^
CANCER:

Myelodysplastic Syndrome

No biomarker
MDS
decitabine/cedazuridine
Sensitive: A1 - Approval
Astex Press Release - 3 weeks
ASXL1 mutation
MDS
venetoclax
Sensitive: C2 – Inclusion Criteria
Blood Cancer J - 3 weeks
ASXL1 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
Blood Cancer J - 3 weeks
No biomarker
MDS
luspatercept-aamt
Sensitive: A1 - Approval
Chr del(5q)
MDS
lenalidomide
Sensitive: A1 - Approval
No biomarker
MDS
azacitidine
Sensitive: A1 - Approval
No biomarker
MDS
decitabine
Sensitive: A1 - Approval
PDGFRA rearrangement
MDS
imatinib
Sensitive: A1 - Approval
CALR mutation
MDS
luspatercept-aamt
Sensitive: A2 - Guideline
CALR mutation
MDS
lenalidomide
Sensitive: A2 - Guideline
MPL W515L
MDS
luspatercept-aamt
Sensitive: A2 - Guideline
MPL W515L
MDS
lenalidomide
Sensitive: A2 - Guideline
JAK2 V617F
MDS
luspatercept-aamt
Sensitive: A2 - Guideline
SF3B1 mutation
MDS
luspatercept-aamt
Sensitive: A2 - Guideline
JAK2 V617F
MDS
lenalidomide
Sensitive: A2 - Guideline
SF3B1 mutation
MDS
lenalidomide
Sensitive: A2 - Guideline
TP53 mutation
MDS
APR-246
Sensitive: B - Late Trials
No biomarker
MDS
Hu5F9-G4
Sensitive: B - Late Trials
DNMT3A mutation + SF3B1 mutation
MDS
lenalidomide
Resistant: B - Late Trials
No biomarker
MDS
MLN4924
Sensitive: B - Late Trials
No biomarker
MDS
lenalidomide
Sensitive: B - Late Trials
Chr del(5)(q31)
MDS
lenalidomide
Sensitive: B - Late Trials
No biomarker
MDS
Hypomethylating agent + MBG453
Sensitive: B - Late Trials
No biomarker
MDS
venetoclax
Sensitive: B - Late Trials
TP53 mutation
MDS
CB-839
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
MDS
ARO-002
Sensitive: C2 – Inclusion Criteria
TP53 mutation
MDS
decitabine
Sensitive: C2 – Inclusion Criteria
TET2 mutation
MDS
azacitidine
Sensitive: C2 – Inclusion Criteria
TP53 mutation
MDS
venetoclax
Sensitive: C2 – Inclusion Criteria
RUNX1 mutation
MDS
venetoclax
Sensitive: C2 – Inclusion Criteria
IDH2 mutation
MDS
enasidenib
Sensitive: C2 – Inclusion Criteria
MECOM mutation + KDM6B mutation
MDS
lenalidomide
Sensitive: C3 – Early Trials
MECOM mutation + KDM6A mutation
MDS
lenalidomide
Sensitive: C3 – Early Trials
RUNX1 mutation
MDS
pembrolizumab
Sensitive: C3 – Early Trials
DNMT3A mutation
MDS
pembrolizumab
Sensitive: C3 – Early Trials
ASXL1 mutation
MDS
pembrolizumab
Sensitive: C3 – Early Trials
TET2 mutation
MDS
pembrolizumab
Sensitive: C3 – Early Trials
BNIP3L elevation
MDS
azacitidine
Sensitive: C3 – Early Trials
LDHA elevation
MDS
azacitidine
Sensitive: C3 – Early Trials
HIF1A overexpression
MDS
azacitidine
Sensitive: C3 – Early Trials
TP53 mutation
MDS
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
PIK3CD mutation
MDS
lenalidomide
Resistant: C3 – Early Trials
PLCG2 mutation
MDS
lenalidomide
Resistant: C3 – Early Trials
AKT3 mutation
MDS
lenalidomide
Resistant: C3 – Early Trials
TMB-H
MDS
Immunotherapy
Sensitive: C3 – Early Trials
SF3B1 K700E
MDS
Hypomethylating agent
Sensitive: C3 – Early Trials
SF3B1 mutation + Chr del(5q)
MDS
lenalidomide
Resistant: C3 – Early Trials
Chr del(20q) + ASXL1 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
Chr del(20q) + ASXL1 deletion
MDS
azacitidine
Resistant: C3 – Early Trials
DNMT3A mutation
MDS
azacitidine
Resistant: C3 – Early Trials
DNMT3A mutation
MDS
decitabine
Resistant: C3 – Early Trials
TP53 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
U2AF1 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
U2AF1 mutation
MDS
decitabine
Resistant: C3 – Early Trials
NPM1 mutation
MDS
decitabine
Sensitive: C3 – Early Trials
RRM1 underexpression
MDS
azacitidine
Sensitive: C3 – Early Trials
Chr del(5q) + TP53 expression
MDS
lenalidomide
Resistant: C3 – Early Trials
Chr del(5)(q31.1)
MDS
lenalidomide
Sensitive: C3 – Early Trials
EZH2 mutation
MDS
venetoclax
Sensitive: C3 – Early Trials
SLFN11 expression
MDS
BGB324
Sensitive: C3 – Early Trials
ANG elevation
MDS
BGB324
Sensitive: C3 – Early Trials
AXL elevation
MDS
BGB324
Sensitive: C3 – Early Trials
JDP2 overexpression
MDS
azacitidine
Sensitive: C3 – Early Trials
SPI1 overexpression
MDS
azacitidine
Sensitive: C3 – Early Trials
Chr del(17p)
MDS
azacitidine
Resistant: C3 – Early Trials
NPM1 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
SETBP1 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
RUNX1 mutation
MDS
azacitidine
Resistant: C3 – Early Trials
IDH1 mutation
MDS
venetoclax + ivosidenib
Sensitive: C3 – Early Trials
TP53 mutation
MDS
MBG453
Sensitive: C3 – Early Trials
ASXL1 deletion
MDS
azacitidine
Resistant: C3 – Early Trials
TP53 mutation
MDS
azacitidine + MBG453
Sensitive: C3 – Early Trials
TP53 mutation
MDS
decitabine + MBG453
Sensitive: C3 – Early Trials
IDH2 mutation
MDS
azacitidine + enasidenib
Sensitive: C3 – Early Trials
ASXL1 mutation
MDS
venetoclax + azacitidine
Sensitive: C3 – Early Trials
TP53 mutation
MDS
pembrolizumab
Sensitive: C4 – Case Studies
BCR-ABL1 fusion
MDS
imatinib
Sensitive: C4 – Case Studies
PCM1-PDGFRB fusion
MDS
imatinib
Sensitive: C4 – Case Studies
PAN3-PSMA2 fusion
MDS
decitabine
Sensitive: C4 – Case Studies
MCL1 expression
MDS
DSP-2033
Sensitive: D – Preclinical